NCT03697798View on ClinicalTrials.gov

A Study Exploring Whooping Cough Protection in Children and Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

April 18, 2018

Primary Completion Date

January 14, 2020

Study Completion Date

January 14, 2020

Conditions
Pertussis
Interventions
BIOLOGICAL

Boostrix®-IPV combination vaccine

A licensed aP (acellular) booster vaccine developed by GlaxoSmithKline.

Trial Locations (3)

FI-20014

University of Turku, Turku

3721 MA

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven

OX3 7LE

Centre for Clinical Vaccinology & Tropical Medicine (CCVTM), Oxford

All Listed Sponsors
collaborator

National Institute for Public Health and the Environment (RIVM)

OTHER_GOV

collaborator

University of Turku

OTHER

lead

University of Oxford

OTHER

NCT03697798 - A Study Exploring Whooping Cough Protection in Children and Adults | Biotech Hunter | Biotech Hunter